Dakota Wealth Management acquired a new stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 17,528 shares of the biopharmaceutical company’s stock, valued at approximately $1,063,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in INCY. Cape Investment Advisory Inc. purchased a new position in shares of Incyte during the 4th quarter worth approximately $25,000. Larson Financial Group LLC raised its stake in shares of Incyte by 4,220.0% during the 4th quarter. Larson Financial Group LLC now owns 432 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 422 shares in the last quarter. Redmont Wealth Advisors LLC purchased a new position in shares of Incyte during the 1st quarter worth approximately $28,000. Riverview Trust Co acquired a new stake in shares of Incyte in the 1st quarter worth approximately $29,000. Finally, Fidelis Capital Partners LLC acquired a new stake in shares of Incyte in the 1st quarter worth approximately $32,000. 96.97% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at Incyte
In other news, insider Thomas Tray sold 1,093 shares of Incyte stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $58.91, for a total transaction of $64,388.63. Following the sale, the insider now owns 21,634 shares of the company’s stock, valued at $1,274,458.94. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, EVP Vijay K. Iyengar sold 15,571 shares of Incyte stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $70.00, for a total transaction of $1,089,970.00. Following the sale, the executive vice president now owns 36,701 shares of the company’s stock, valued at $2,569,070. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Thomas Tray sold 1,093 shares of the business’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $58.91, for a total value of $64,388.63. Following the sale, the insider now directly owns 21,634 shares in the company, valued at approximately $1,274,458.94. The disclosure for this sale can be found here. Insiders sold a total of 45,282 shares of company stock worth $2,876,911 over the last ninety days. Company insiders own 17.50% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on Incyte
Incyte Stock Up 2.0 %
NASDAQ:INCY traded up $1.25 during mid-day trading on Tuesday, reaching $64.51. The stock had a trading volume of 487,129 shares, compared to its average volume of 2,496,209. The company has a market capitalization of $14.49 billion, a price-to-earnings ratio of 19.17, a price-to-earnings-growth ratio of 1.14 and a beta of 0.73. Incyte Co. has a 1-year low of $50.27 and a 1-year high of $70.36. The stock’s 50 day simple moving average is $62.64 and its two-hundred day simple moving average is $58.86. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.92 and a quick ratio of 3.43.
Incyte (NASDAQ:INCY – Get Free Report) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60). Incyte had a net margin of 2.52% and a return on equity of 0.75%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the firm earned $0.77 earnings per share. The business’s revenue was up 9.3% on a year-over-year basis. Equities analysts anticipate that Incyte Co. will post 3.35 EPS for the current year.
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Featured Articles
- Five stocks we like better than Incyte
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What is Short Interest? How to Use It
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Technology Stocks Explained: Here’s What to Know About Tech
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.